Artificial intelligence (AI) and machine learning (ML) are rapidly transforming the medical device industry — reshaping how diseases are detected, how clinicians make decisions, and how patients experience care. From AI-powered imaging software that flags early-stage cancer to wearable sensors that predict cardiac events before they happen, intelligent devices are no longer a distant promise. They are here, they are regulated, and their impact is accelerating.
As of 2022, the FDA had authorized over 500 AI-enabled medical devices — the vast majority in radiology — with new clearances arriving at an unprecedented pace. For medical device companies, understanding the AI landscape means understanding not only the technology, but also the regulatory framework that governs it.
In this article, we explore the core applications of AI in medical devices, the FDA's evolving regulatory approach, and the key considerations for companies developing or incorporating AI/ML-based technologies.
What is Artificial Intelligence in Medical Devices?
Artificial intelligence in medical devices refers to the use of algorithms and statistical models — including machine learning, deep learning, and neural networks — to perform tasks that traditionally required human cognitive ability. These tasks include pattern recognition, classification, prediction, and recommendation generation based on complex, multi-dimensional data.
When AI performs a medical purpose — such as aiding in diagnosis, treatment selection, or disease monitoring — the software may be classified by the FDA as a Software as a Medical Device (SaMD). This classification subjects it to premarket review and post-market obligations commensurate with the risk it poses to patients.
Key AI/ML Terms in the Medical Device Context
Machine Learning (ML)
Algorithms that learn patterns from data without being explicitly programmed.
Deep Learning
A subset of ML using multi-layered neural networks to extract hierarchical features from data.
Locked Algorithm
An AI model that does not change its behavior after deployment without a new submission to the FDA.
Adaptive Algorithm
An AI model that can continuously learn and update after deployment — posing unique regulatory challenges.
SaMD
Software as a Medical Device — software intended to be used for medical purposes without being part of a hardware medical device.
PCCP
Predetermined Change Control Plan — a regulatory mechanism allowing pre-approved post-market algorithm updates.
Key Applications of AI Across Medical Device Categories
AI is being applied across virtually every clinical domain. Here are the most prominent and fastest-growing areas:
Radiology & Medical Imaging
AI algorithms analyze X-rays, CT scans, and MRIs to detect anomalies — from tumors and fractures to early-stage diseases — with accuracy that rivals or exceeds trained radiologists. Over 75% of FDA-authorized AI devices are in the radiology space.
Cardiology
Machine learning models interpret ECGs, echocardiograms, and wearable sensor data to detect arrhythmias, predict heart failure risk, and flag silent atrial fibrillation in real time.
Pathology
Digital pathology platforms use deep learning to scan tissue slides and identify cancerous cells with high sensitivity, reducing inter-observer variability and turnaround time.
Clinical Decision Support
AI-powered software integrates patient data across EHRs, labs, and imaging to deliver evidence-based clinical decision support — helping clinicians prioritize care and reduce diagnostic errors.
Continuous Monitoring
Connected devices and wearables leverage AI to continuously track vital signs, glucose levels, and neurological activity, alerting care teams before adverse events occur.
Surgical Robotics
AI enhances robotic-assisted surgery by providing real-time anatomical guidance, motion scaling, and tremor filtration — improving precision and reproducibility in complex procedures.
FDA-Authorized AI-Enabled Medical Devices — Distribution by Specialty (2022)
Source: FDA AI-Enabled Medical Devices List
Benefits and Opportunities
The integration of AI into medical devices offers transformative potential for patients, clinicians, and healthcare systems:
Earlier Disease Detection
AI models can identify subtle imaging or biosignal patterns that indicate disease onset long before symptoms appear — enabling earlier intervention and improved outcomes.
Reduced Clinician Burden
By automating routine analysis tasks — reviewing imaging studies, flagging abnormal lab values, triaging incoming data — AI frees clinicians to focus on higher-complexity decision making and patient interaction.
Democratizing Expertise
AI-enabled devices can deliver specialist-level insights in resource-limited settings and underserved communities, reducing geographic and socioeconomic disparities in healthcare quality.
Personalized Medicine
By learning from large, diverse patient populations, AI models can tailor diagnostic thresholds and treatment recommendations to individual patient profiles, moving medicine closer to true personalization.
Continuous Improvement
Unlike static rule-based systems, ML-based devices can improve over time as they are exposed to new data — a capability not possible with traditional medical device software.
The FDA Regulatory Framework for AI/ML Medical Devices
Regulating AI-based medical devices presents unique challenges. Unlike traditional devices, AI algorithms can adapt and evolve after deployment — a capability the FDA's traditional 510(k) framework was not designed to accommodate. In response, the FDA has been actively modernizing its approach.
Software as a Medical Device (SaMD)
The FDA classifies AI-driven software that performs a medical function — diagnosis, treatment, prevention — as a Software as a Medical Device (SaMD). These products are subject to premarket review requirements commensurate with their risk level.
510(k) and De Novo Pathways
Most AI/ML-enabled Class II devices are cleared via the 510(k) pathway by demonstrating substantial equivalence to a predicate. Novel AI devices with no predicate may pursue the De Novo pathway to establish a new device classification.
Predetermined Change Control Plans (PCCPs)
Because AI models can improve over time with new data, the FDA has developed the PCCP framework — allowing manufacturers to pre-specify the types of algorithm changes that can be made post-clearance without requiring a new submission, as long as safety and effectiveness are maintained.
Total Product Lifecycle (TPLC) Approach
The FDA's TPLC approach recognizes that AI devices evolve. It emphasizes robust post-market surveillance, real-world performance monitoring, and transparency with clinicians and patients about AI-generated outputs.
Good Machine Learning Practice (GMLP)
The FDA, alongside Health Canada and the UK's MHRA, has outlined ten guiding principles for Good Machine Learning Practice — covering data management, model training, bias mitigation, and transparency throughout the product lifecycle.
Challenges and Considerations
Despite its enormous promise, AI in medical devices also carries risks and unresolved challenges that developers and regulators must address:
Algorithmic Bias
AI models trained on non-representative datasets can perform poorly for underrepresented populations, potentially worsening health disparities.
Explainability (Black Box Problem)
Many deep learning models cannot clearly explain their outputs, making it difficult for clinicians to understand, trust, or override AI-generated recommendations.
Data Quality & Privacy
AI model performance depends critically on the quality, quantity, and representativeness of training data — and the collection of that data raises significant patient privacy concerns.
Regulatory Lag
The pace of AI innovation is outpacing regulatory frameworks, creating uncertainty for developers about what evidence is required and how adaptive algorithms will be assessed.
Cybersecurity
As AI devices become increasingly connected, they become potential targets for adversarial attacks that could manipulate model inputs or outputs — with direct patient safety consequences.
Clinician Adoption
Meaningful adoption requires that clinicians trust, understand, and know how to appropriately rely on AI outputs — demanding education, workflow integration, and robust human oversight mechanisms.
Biomedisca's Perspective: AI as Clinical Intelligence Infrastructure
At Biomedisca, we believe that AI's greatest potential in medicine lies not in replacing clinicians, but in building the clinical intelligence infrastructure that enables them to act earlier, more precisely, and with greater confidence. Our platforms — Medora and CORDx — are built on the principle that AI should be interpretable, evidence-based, and deeply integrated into the diagnostic workflow.
This means designing AI not as a black box that produces an answer, but as a transparent analytical layer that surfaces the right information at the right moment — so the clinician remains in control of the most consequential decisions.
As the regulatory landscape continues to evolve, companies that invest early in robust data governance, validation rigor, and explainable model design will be best positioned to bring safe, effective AI-enabled devices to patients at scale.
"The future of diagnostics is not a machine making decisions for clinicians — it is intelligent infrastructure that makes every clinician's decision faster, smarter, and more certain."
— Dr. Max Foroughi, Founder & CEO, Biomedisca
